Idiopathic inflammatory myopathies are rare autoimmune diseases that affect muscle tissues. The first line of treatment comprises of immunosuppressive agents and steroids. However, refractory myopathy is a challenge owing to clinical heterogeneity.
Rotella et al. (2018) presented three case studies where tacrolimus (TAC), an immunosuppressive agent used in allegeneic organ transplant, was introduced to the ongoing combination treatment regime resulting in clinical improvement. The study emphasized on randomized controlled trials and establishment of clinical management guidelines for such rare disorders.